Evolving role of 225Ac-PSMA radioligand therapy in metastatic castration-resistant prostate cancer—a systematic review and meta-analysis
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Urology,Oncology
Link
https://www.nature.com/articles/s41391-021-00349-w.pdf
Reference29 articles.
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
2. Helgstrand JT, Røder MA, Klemann N, Toft BG, Lichtensztajn DY, Brooks JD, et al. Trends in incidence and 5‐year mortality in men with newly diagnosed, metastatic prostate cancer—a population‐based analysis of 2 national cohorts. Cancer. 2018;124:2931–8.
3. Ingrosso G, Detti B, Scartoni D, Lancia A, Giacomelli I, Baki M, et al. Current therapeutic options in metastatic castration-resistant prostate cancer. Semin Oncol. 2018;45:303–15.
4. Wright GL Jr, Haley C, Beckett ML, Schellhammer PF. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol. 1995;1:18–28.
5. Yadav MP, Ballal S, Sahoo RK, Dwivedi SN, Bal C. Radioligand therapy with 177Lu-PSMA for metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. AJR Am J Roentgenol. 2019;213:275–85.
Cited by 43 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Automated preparation of Actinium-225 with accelerator-based production from irradiated natural thorium targets;Separation and Purification Technology;2025-02
2. Advances in PSMA Alpha Theragnostics;Seminars in Nuclear Medicine;2024-07
3. Prostate-specific Membrane Antigen: Alpha-labeled Radiopharmaceuticals;PET Clinics;2024-07
4. Peculiar Pattern of Response Following [225Ac]Ac-PSMA Therapy: A Case Report with ‘PSA Pseudoregression’ Response Pattern;Nuklearmedizin - NuclearMedicine;2024-05-17
5. Implementing Ac-225 labelled radiopharmaceuticals: practical considerations and (pre-)clinical perspectives;EJNMMI Radiopharmacy and Chemistry;2024-02-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3